Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer

Схожие документы

• Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy
  по: Lazzari, Chiara, et al.
  Опубликовано: (2019)
• Mechanisms of resistance to osimertinib
  по: Lazzari, Chiara, et al.
  Опубликовано: (2020)
• Co-mutations in EGFR driven non-small cell lung cancer
  по: Rosell, Rafael, et al.
  Опубликовано: (2019)
• Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer
  по: Lazzari, Chiara, et al.
  Опубликовано: (2018)
• Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
  по: Bracht, Jillian Wilhelmina Paulina, et al.
  Опубликовано: (2019)